SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001737287-24-000041
Filing Date
2024-05-13
Accepted
2024-05-13 16:03:40
Documents
71
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q allo-20240331.htm   iXBRL 10-Q 1287718
2 EX-10.1 allo-20240331xex101.htm EX-10.1 25866
3 EX-31.1 allo-20240331xex311.htm EX-31.1 9782
4 EX-31.2 allo-20240331xex312.htm EX-31.2 9747
5 EX-32.1 allo-20240331xex321.htm EX-32.1 7005
  Complete submission text file 0001737287-24-000041.txt   6531187

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20240331.xsd EX-101.SCH 57656
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT allo-20240331_cal.xml EX-101.CAL 51669
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT allo-20240331_def.xml EX-101.DEF 334315
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20240331_lab.xml EX-101.LAB 598482
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20240331_pre.xml EX-101.PRE 460656
74 EXTRACTED XBRL INSTANCE DOCUMENT allo-20240331_htm.xml XML 705180
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38693 | Film No.: 24938924
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)